Mouse model uncovers how lung cells manage severe asthma inflammation
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...
Medscape3d
Patients With Asthma and COPD At Increased Cancer Risk From Microplastics
Individuals with asthma and chronic obstructive pulmonary disease (COPD) were more vulnerable than healthy controls to ...
News Medical on MSN1d
Researchers find that blocking specific proteins in immune cells can reduce or reverse lung scarring
A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...
technologynetworks19h
Targeting Immune Cell Proteins To Reverse Lung Scarring
Researchers at Duke-NUS Medical School have identified YAP and TAZ proteins as key drivers of pulmonary fibrosis. Blocking ...
News Medical on MSN2d
Researchers develop mouse model to study neutrophilic asthma
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...
Science Daily2d
A treatment-resistant, severe type of asthma successfully modeled in mice
Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.
Science Daily1d
Pulmonary fibrosis: Study targets proteins to reverse lung scarring
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
technologynetworks2d
Treatment-Resistant Asthma Modeled in Mice for the First Time
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...